Clinical Trial Update: A Compassionate Use (CU) Program of Odronextamab

View source ↗

Summary

Compassionate-use program update for odronextamab in relapsed or refractory B-cell lymphomas, including follicular lymphoma and diffuse large B-cell lymphoma. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• High-grade B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Odronextamab (odronextamab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Relapsed or Refractory (R/R) Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL) | Status: AVAILABLE